Prospective computational design and in vitro bio-analytical tests of new chemical entities as potential selective CYP17A1 lyase inhibitors

[EN] The development and advancement of prostate cancer (PCa) into stage 4, where it metastasize, is a major problem mostly in elder males. The growth of PCa cells is stirred up by androgens and androgen receptor (AR). Therefore, therapeutic strategies such as blocking androgens synthesis and inhibiting AR binding have been explored in recent years. However, recently approved drugs (or in clinical phase) failed in improving the expected survival rates for this metastatic-castration resistant prostate cancer (mCRPC) patients. The selective CYP17A1 inhibition of 17,20-lyase route has emerged as a novel strategy. Such inhibition blocks the production of androgens everywhere they are found in the body. In this work, a three dimensional-quantitative structure activity relationship (3D-QSAR) pharmacophore model is developed on a diverse set of non-steroidal inhibitors of CYP17A1 enzyme. Highly active compounds are selected to define a six-point pharmacophore hypothesis with a unique geometrical arrangement fitting the following description: two hydrogen bond acceptors (A), two hydrogen bond donors (D) and two aromatic rings (R). The QSAR model showed adequate predictive statistics. The 3D-QSAR model is further used for database virtual screening of potential inhibitory hit structures. Density functional theory (DFT) optimization provides the electronic properties explaining the reactivity of the hits. Docking simulations discovers hydrogen bonding and hydrophobic interactions as responsible for the binding affinities of hits to the CYP17A1 Protein Data Bank structure. 13 hits from the database search (including five derivatives) are then synthesized in the laboratory as different scaffolds. Ultra high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) in vitro experiments reveals three new chemical entities (NCEs) with half maximal inhibitory concentration (IC50) values against the lyase route at mid-micromolar range with favorable selectivity to the lyase over the hydroxylase route (one of them with null hydroxylase inhibition). Thus, prospective computational design has enabled the design of potential lead lyase-selective inhibitors for further studies.This work research work was supported financially in part by the National Research Foundation of South Africa and First Rand Foundation (UID: 112151). This work was also made possible through funding by the Research Capacity Development Initiative-South African Medical Research Council (RCDI-SAMRC). The content hereof is the sole responsibility of the authors and does not necessarily represent the official views of NRF and SAMRC. The authors would like to acknowledge the Centre for High Performance Computing for allowing access to their resources for molecular modeling. Xenogesis Ltd is greatly acknowledge for performing bioanalytical experiments, as an outsourced services. Enamine LTD is greatly acknowledge for custom synthesis of the compounds, as an outsourced service.Gumede, N.; Nxumalo, W.; Bisetty, K.; Escuder Gilabert, L.; Medina-Hernández, M.; Sagrado Vives, S. (2020). Prospective computational design and in vitro bio-analytical tests of new chemical entities as potential selective CYP17A1 lyase inhibitors. Bioorganic Chemistry. 94:1-16. https://doi.org/10.1016/j.bioorg.2019.10346211694Nnane, I. P., Kato, K., Liu, Y., Long, B. J., Lu, Q., Wang, X., … Brodie, A. (1999). Inhibition of Androgen Synthesis in Human Testicular and Prostatic Microsomes and in Male Rats by Novel Steroidal Compounds*. Endocrinology, 140(6), 2891-2897. doi:10.1210/endo.140.6.6832C. Jagusch, M. Negri, U.E. Hille, Q. Hu, M. Bartels, K. Jahn-Hoffmann, M.A.E. Pinto-Bazurco Mendieta, B. Rodenwaldt, U. Müller-Vieira, D. Schmidt, T. Lauterbach, M. Recanatini, A. Cavalli, R.W. Hartmann, Synthesis, biological evaluation and molecular modelling studies of methylene imidazole substituted biaryls as inhibitors of human 17α-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure, Bioorg. Med. Chem. J. 16 (2008) 1992–2010.Haider, S. M., Patel, J. S., Poojari, C. S., & Neidle, S. (2010). Molecular Modeling on Inhibitor Complexes and Active-Site Dynamics of Cytochrome P450 C17, a Target for Prostate Cancer Therapy. Journal of Molecular Biology, 400(5), 1078-1098. doi:10.1016/j.jmb.2010.05.069Yap, T. A., Carden, C. P., Attard, G., & de Bono, J. S. (2008). Targeting CYP17: established and novel approaches in prostate cancer. Current Opinion in Pharmacology, 8(4), 449-457. doi:10.1016/j.coph.2008.06.004Gianti, E., & Zauhar, R. J. (2012). Modeling Androgen Receptor Flexibility: A Binding Mode Hypothesis of CYP17 Inhibitors/Antiandrogens for Prostate Cancer Therapy. Journal of Chemical Information and Modeling, 52(10), 2670-2683. doi:10.1021/ci3002342G. Schaefer, J.M. Mosquera, R. Ramoner, K. Park, A. Romanel, E. Steiner, W. Horninger, J. Bektic, M. Ladurner-Rennau, M.A. Rubin, F. Demichelis, H. Klocker, Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer, Prostate Cancer P. D. 16 (2013) 132–138.G. Lippolis, A. Edsjö, U.H. Stenman, A. Bjartell, A high density tissue micro-array from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells, Cancer P. D. 16 (2013) 145–150.Ferraldeschi, R., & de Bono, J. (2013). Agents That Target Androgen Synthesis in Castration-Resistant Prostate Cancer. The Cancer Journal, 19(1), 34-42. doi:10.1097/ppo.0b013e31827e0b6fHu, Q., Jagusch, C., Hille, U. E., Haupenthal, J., & Hartmann, R. W. (2010). Replacement of Imidazolyl by Pyridyl in Biphenylmethylenes Results in Selective CYP17 and Dual CYP17/CYP11B1 Inhibitors for the Treatment of Prostate Cancer. Journal of Medicinal Chemistry, 53(15), 5749-5758. doi:10.1021/jm100317bPinto-Bazurco Mendieta, M. A. E., Hu, Q., Engel, M., & Hartmann, R. W. (2013). Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases. Journal of Medicinal Chemistry, 56(15), 6101-6107. doi:10.1021/jm400484pT. Kaku, S. Tsujimoto, N. Matsunaga, T. Tanaka, T. Hara, M. Yamaoka, M. Kusaka, A. Tasaka, 17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17, 20-lyse inhibitors, Bioorg. Med. Chem. 19 (2011) 2428–2442.Bruno, R. D., Vasaitis, T. S., Gediya, L. K., Purushottamachar, P., Godbole, A. M., Ates-Alagoz, Z., … Njar, V. C. O. (2011). Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): Head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model. Steroids, 76(12), 1268-1279. doi:10.1016/j.steroids.2011.06.002MILLER, W. L. (1988). Molecular Biology of Steroid Hormone Synthesis*. Endocrine Reviews, 9(3), 295-318. doi:10.1210/edrv-9-3-295Zhu, H., & Garcia, J. A. (2013). Targeting the Adrenal Gland in Castration-Resistant Prostate Cancer: A Case for Orteronel, a Selective CYP-17 17,20-Lyase Inhibitor. Current Oncology Reports, 15(2), 105-112. doi:10.1007/s11912-013-0300-1Akhtar, M. K., Kelly, S. L., & Kaderbhai, M. A. (2005). Cytochrome b5 modulation of 17α hydroxylase and 17–20 lyase (CYP17) activities in steroidogenesis. Journal of Endocrinology, 187(2), 267-274. doi:10.1677/joe.1.06375Yin, L., & Hu, Q. (2013). CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents. Nature Reviews Urology, 11(1), 32-42. doi:10.1038/nrurol.2013.274DeVore, N. M., & Scott, E. E. (2012). Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. Nature, 482(7383), 116-119. doi:10.1038/nature10743Bird, I. M., & Abbott, D. H. (2016). The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature. The Journal of Steroid Biochemistry and Molecular Biology, 163, 136-146. doi:10.1016/j.jsbmb.2016.04.021Vasaitis, T. S., Bruno, R. D., & Njar, V. C. O. (2011). CYP17 inhibitors for prostate cancer therapy. The Journal of Steroid Biochemistry and Molecular Biology, 125(1-2), 23-31. doi:10.1016/j.jsbmb.2010.11.005Gomez, L., Kovac, J. R., & Lamb, D. J. (2015). CYP17A1 inhibitors in castration-resistant prostate cancer. Steroids, 95, 80-87. doi:10.1016/j.steroids.2014.12.021De Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., … Scher, H. I. (2011). Abiraterone and Increased Survival in Metastatic Prostate Cancer. New England Journal of Medicine, 364(21), 1995-2005. doi:10.1056/nejmoa1014618Kaku, T., Hitaka, T., Ojida, A., Matsunaga, N., Adachi, M., Tanaka, T., … Tasaka, A. (2011). Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorganic & Medicinal Chemistry, 19(21), 6383-6399. doi:10.1016/j.bmc.2011.08.066Salvador, J. A. R., Pinto, R. M. A., & Silvestre, S. M. (2013). Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases. The Journal of Steroid Biochemistry and Molecular Biology, 137, 199-222. doi:10.1016/j.jsbmb.2013.04.006Njar, V. C. O., & Brodie, A. M. H. (2015). Discovery and Development of Galeterone (TOK-001 or VN/124-1) for the Treatment of All Stages of Prostate Cancer. Journal of Medicinal Chemistry, 58(5), 2077-2087. doi:10.1021/jm501239fAlzate-Morales, J. H., Vergara-Jaque, A., & Caballero, J. (2010). Computational Study on the Interaction of N1 Substituted Pyrazole Derivatives with B-Raf Kinase: An Unusual Water Wire Hydrogen-Bond Network and Novel Interactions at the Entrance of the Active Site. Journal of Chemical Information and Modeling, 50(6), 1101-1112. doi:10.1021/ci100049hPurushottamachar, P., Khandelwal, A., Vasaitis, T. S., Bruno, R. D., Gediya, L. K., & Njar, V. C. O. (2008). Potent anti-prostate cancer agents derived from a novel androgen receptor down-regulating agent. Bioorganic & Medicinal Chemistry, 16(7), 3519-3529. doi:10.1016/j.bmc.2008.02.031Bonomo, S., Hansen, C. H., Petrunak, E. M., Scott, E. E., Styrishave, B., Jørgensen, F. S., & Olsen, L. (2016). Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors. Scientific Reports, 6(1). doi:10.1038/srep29468[Takeda announces termination of Orteronel (TAK-700) development for prostate cancer in Japan, USA and Europe, 2014 [Press release], http://www.takeda.com/newsreleases Accessed: 04/07/2018.Giangreco, I., Cosgrove, D. A., & Packer, M. J. (2013). An Extensive and Diverse Set of Molecular Overlays for the Validation of Pharmacophore Programs. Journal of Chemical Information and Modeling, 53(4), 852-866. doi:10.1021/ci400020aC.G. Wermuth, C.R. Ganellin, P. Lindberg, L.A. Mitscher, ; “Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998)”, Pure. Appl. Chem. J. 70 (1998) 1129–1143.Schuster, D., Kowalik, D., Kirchmair, J., Laggner, C., Markt, P., Aebischer-Gumy, C., … Adamski, J. (2011). Identification of chemically diverse, novel inhibitors of 17β-hydroxysteroid dehydrogenase type 3 and 5 by pharmacophore-based virtual screening. The Journal of Steroid Biochemistry and Molecular Biology, 125(1-2), 148-161. doi:10.1016/j.jsbmb.2011.01.016Xiao, F., Yang, M., Xu, Y., & Vongsangnak, W. (2015). Comparisons of Prostate Cancer Inhibitors Abiraterone and TOK-001 Binding with CYP17A1 through Molecular Dynamics. Computational and Structural Biotechnology Journal, 13, 520-527. doi:10.1016/j.csbj.2015.10.001Petrunak, E. M., DeVore, N. M., Porubsky, P. R., & Scott, E. E. (2014). Structures of Human Steroidogenic Cytochrome P450 17A1 with Substrates. Journal of Biological Chemistry, 289(47), 32952-32964. doi:10.1074/jbc.m114.610998M.A.E. Pinto-Bazurco Mendieta, M. Negri, C. Jagusch, U. Müller-Vieira, T. Lauterbach, R.W. Hartmann, Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer, J. Med. Chem. 51 (2008) 5009–5018.Zhuang, Y., Wachall, B. G., & Hartmann, R. W. (2000). Novel imidazolyl and triazolyl substituted biphenyl compounds: synthesis and evaluation as nonsteroidal inhibitors of human 17α-hydroxylase-C17, 20-Lyase (P450 17). Bioorganic & Medicinal Chemistry, 8(6), 1245-1252. doi:10.1016/s0968-0896(00)00076-6Hu, Q., Yin, L., Jagusch, C., Hille, U. E., & Hartmann, R. W. (2010). Isopropylidene Substitution Increases Activity and Selectivity of Biphenylmethylene 4-Pyridine Type CYP17 Inhibitors. Journal of Medicinal Chemistry, 53(13), 5049-5053. doi:10.1021/jm100400aDeora, G. S., Joshi, P., Rathore, V., Kumar, K. L., Ohlyan, R., & Kandale, A. (2012). Pharmacophore modeling and 3D QSAR analysis of isothiazolidinedione derivatives as PTP1B inhibitors. Medicinal Chemistry Research, 22(7), 3478-3484. doi:10.1007/s00044-012-0349-7Jain, S. V., Ghate, M., Bhadoriya, K. S., Bari, S. B., Sugandhi, G., & Mandwal, P. (2012). 3D-QSAR pharmacophore modeling and in silico screening of phospholipase A2α inhibitors. Medicinal Chemistry Research, 22(7), 3096-3108. doi:10.1007/s00044-012-0316-3Gumede, N. J., Singh, P., Sabela, M. I., Bisetty, K., Escuder-Gilabert, L., Medina-Hernández, M. J., & Sagrado, S. (2012). Experimental-Like Affinity Constants and Enantioselectivity Estimates from Flexible Docking. Journal of Chemical Information and Modeling, 52(10), 2754-2759. doi:10.1021/ci300335mAttard, G., Belldegrun, A. S., & de Bono, J. S. (2005). Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU International, 96(9), 1241-1246. doi:10.1111/j.1464-410x.2005.05821.xL. Wang, Y. Deng, Y. Wu, B. Kim, D.N. LeBard, D. Wandschneider, M. Beachy, R.A. Friesner, R. Abel, Accurate modeling of scaffold hopping transformations in drug discovery, J. Chem. Theory Comput. 13 (2017) 42−54.B. Kuhn, M. Tichý, L. Wang, S. Robinson, R.E. Martin, A. Kuglstatter, J. Benz, M. Giroud, T. Schirmeister, R. Abel, F. Diederich, J. Hert, Prospective evaluation of free energy calculations for the prioritization of Cathepsin L Inhibitors, J. Med. Chem. 60 (2017) 2485−2497.Maestro, version 10.2, Schrödinger, LLC, New York, NY, 2015.MacroModel, version 10.8, Schrödinger, LLC, New York, NY, 2015.Phase, version 4.3, Schrödinger, LLC, New York, NY, 2015.Dixon, S. L., Smondyrev, A. M., Knoll, E. H., Rao, S. N., Shaw, D. E., & Friesner, R. A. (2006). PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. Journal of Computer-Aided Molecular Design, 20(10-11), 647-671. doi:10.1007/s10822-006-9087-6Tawari, N. R., & Degani, M. S. (2011). Pharmacophore Modeling and Density Functional Theory Analysis for A Series of Nitroimidazole Compounds with Antitubercular Activity. Chemical Biology & Drug Design, 78(3), 408-417. doi:10.1111/j.1747-0285.2011.01161.xVirtual Screening Workflow. Schrödinger, LLC, New York, NY, 2015.Jaguar, version 8.8, Schrödinger, LLC, New York, NY, 2015.http://www.enamine.net/ [accessed 05/11/2014]